Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Pfizer
Woman and Man Max 99 years
FoldRx Pharmaceuticals, a Pfizer Company
Update Il y a 3 ans
A double-blind, randomized study looking at the efficacy, safety and tolerability of tafamidis meglumine (PF-06291826) 20 mg or 80 mg compared to placebo when taken daily by oral administration mouth in subjects diagnosed with transthyretin cardiomyopathy (TTR-CM)
The primary objective of this study is to assess the efficacy of an oral dose of 20 mg or 80 mg tafamidis meglumine soft-gel capsules based on all-cause mortality and on frequency of cardiovascular-re...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years and 75 years
Pfizer
Update Il y a 3 ans
Pfizer XRP4174D-3001 : Essai de phase 3, randomisé comparant l’association au cisplatine de l’hydrochloride d’irinotécan ou de l’étoposide, chez des patients ayant un cancer du poumon à petites cellules de stade avancé. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
Open Label, Randomised Multicentre Phase III Study Of Irinotecan Hydrochloride (Campto (Registered)) And Cisplatin Versus Etoposide And Cisplatin In Chemotherapy Naive Patients With Extensive Disease ...
Country
France
organs
Poumon, type à petites cellules
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Wyeth Pharmaceuticals Inc., acting through its division Wyeth research, a Pfizer company
Update Il y a 3 ans
Randomized, Parallel, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of SBI-087 in Seropositive Subjects With Active Rheumatoid Arthritis on a Stable Background of Methotrexate
To evaluate clinical efficacy and safety of 4 SBI-087 SC dosing regimens versus placebo in seropositive subjects with active RA on a stable background of MTX
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc 235 East 42nd Street, New York, NY10017
Update Il y a 3 ans
RANDOMIZED, DOUBLE-BLIND PHASE 2 STUDY OF AXITINIB (AG-013736) WITH OR WITHOUT DOSE TITRATION IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
To compare the objective response rate (ORR) in patients receiving axitinib with or without dose titration (Arms A and B)
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Limited
Update Il y a 3 ans
AN INTERNATIONAL, MULTICENTER, LARGE SIMPLE TRIAL (LST) TO EVALUATE THE LONG-TERM PULMONARY AND CARDIOVASCULAR SAFETY OF EXUBERA® IN PATIENTS WITH DIABETES MELLITUS
The primary objective of this study is to estimate the relative risk of a persistent decline in FEV1 exceeding 20% from baseline among subjects with diabetes randomized to Exubera as compared with tho...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Pfizer
Update Il y a 3 ans
Pfizer A0081128 COPE : Essai de phase 4 randomisé, en double aveugle, évaluant l’efficacité et la tolérance de la prégabalin, en traitement de la douleur, chez des patients ayant des métastases osseuses. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité et la tolérance de la prégabalin pour traiter la douleur osseuse, chez des patients ayant un cancer avec des métastases osseuses. Les patients seron...
Country
France
organs
Métastases osseuses
,
Os
,
Tumeurs solides
Specialty
Autres (cryothérapie, radiofréquence, homéopathie,...)
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Pfizer Limited, Ramsgate Road, Sandwich, CT13 9NJ Kent, UK
Update Il y a 3 ans
A PARALLEL-GROUP, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER DOSE RESPONSE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF- 00885706, A 5-HT4 RECEPTOR PARTIAL AGONIST, AS ADD-ON THERAPY TO ESOMEPRAZOLE FOR THE RELIEF OF SYMPTOMS IN SUBJECTS WITH GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD) WHO HAVE A POOR RESPONSE TO PROTON PUMP INHIBITOR (PPI) TREATMENT
To understand the dose-response characteristics of PF-00885706 for efficacy in terms of symptomatic relief when used as add-on treatment to Esomeprazole 20mg (standard PPI treatment), in subjects with...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 3 ans
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, SAFETY AND EFFICACY STUDY OF SITAXSENTAN SODIUM IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION
The primary objective of this study is to evaluate the efficacy of sitaxsentan (100 mg dose) as compared to placebo in the treatment of subjects with PAH for 12 weeks, as determined by change from the...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Pfizer limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK
Update Il y a 3 ans
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED CROSSOVER STUDY OF THE EFFICACY OF FESOTERODINE IN INCREASING URETHRAL PRESSURE IN STRESS URINARY INCONTINENCE PATIENTS
• To determine whether fesoterodine increases urethral tone relative to placebo in SUI patients.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman
Between 18 years
and 99 years
Pfizer
Update Il y a 3 ans
PALOMA-3 : Essai de phase 3 randomisé, en double-aveugle, évaluant l’efficacité de l’association du palbociclib (PD-0332991) à du fulvestrant, chez des patientes ayant un cancer du sein métastatique RH+/HER2- en progression après un traitement hormonal. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est de comparer l’efficacité du fulvestrant associé ou non à du palbociclib, chez des patientes ayant un cancer du sein RH+/HER2- métastatique, en progression après un traiteme...
Country
France
organs
Sein
Specialty
Thérapies Ciblées
,
Hormonothérapie
Essai clos aux inclusions
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next